Malaria Topoisomerase inhibitors

疟疾拓扑异构酶抑制剂

• 批准号: 9404285
• 负责人: PRADIPSINH K. RATHOD
• 金额: $ 49万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-02-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9404285
• 关键词: Aminacrine; Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Artemisinins; Binding Proteins; Biological; Biological Assay; Budgets; Cell Proliferation; Cells; Cessation of life; Chemicals; Clinical; Clinical Data; Communities; Complex; Crystallization; DHODH gene; DNA; DNA Topoisomerases; Development; Dihydroorotate dehydrogenase; Distant; Drug Kinetics; Drug Targeting; Drug resistance; Effectiveness; Enzyme Inhibition; Enzymes; Evaluation; Funding; Future; Genetic Transcription; Genome; Grant Review; Human; In Vitro; Individual; Intervention; Ion Channel; Laboratories; Lead; Learning; Life Cycle Stages; Liver; Malaria; Metabolic; Metabolism; Modernization; Monitor; Nuclear; Parasites; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Plasmodium; Plasmodium falciparum; Plasmodium vivax; Plastids; Property; Prophylactic treatment; Research; Research Personnel; Resources; Rodent; Roentgen Rays; SCID Mice; Safety; Secure; Series; Solubility; Streptococcus; Structure; Structure-Activity Relationship; Suggestion; Testing; Topoisomerase; Topoisomerase II; Topoisomerase Inhibitors; Topoisomerase-II Inhibitor; United States National Institutes of Health; Validation; Work; antimicrobial drug; base; cell killing; clinical candidate; drug development; drug discovery; enzyme activity; experience; improved; inhibitor/antagonist; knowledge base; lead optimization; mitochondrial genome; mouse model; nanomolar; new therapeutic target; novel; pathogen; pre-clinical; programs; protein structure; public health relevance; pyronaridine; repaired; resistance frequency; response; scaffold; success; targeted agent; tool; transmission process

 DESCRIPTION (provided by applicant): Yearly, malaria kills 0.5 million people and infects over 300 million individuals. Few enzymes are unambiguous targets of approved antimalarials, so new high-value metabolic targets and their inhibitors are needed. Many clinically approved antibacterial and anticancer agents target DNA topoisomerases. While the community has lacked pure and stable malarial topoisomerases to work with, there are intriguing hints from preliminary data that clinically-approved antimalarials, such as pyronaridine, may inhibit malaria topoisomerases. A three-year NIH-funded research program has allowed our team to express large quantities of stable malaria topoisomerases, to setup robust assays for Plasmodium falciparum topoisomerase II and related enzymes, and to obtain the first x-ray crystal structure of a malarial topoisomerase II. With these resources, in Aim 1, we will start a thorough exploration of cell-active antimalarials to identify front-runner PfTopoII inhibitors for optimizaton. In Aims 2 and 3, iterative medicinal chemistry will be guided by inhibition of enzyme and cell proliferation, target validation, PK-PD studies, safety evaluations, and activity against different stages of the parasite life-cycle, all to help deliver an antimalarial preclinical candidate. Based on our previous experiences, learnings, and success with malarial dihydroorotate dehydrogenase (DHODH) inhibitors, we are confident in our ability to develop antimalarials directed at P. falciparum and P. vivax topoisomerases that have clinical potential.

 描述（由申请人提供）：每年，疟疾造成50万人死亡，3亿多人感染。很少有酶是已批准的抗疟药的明确靶点，因此需要新的高价值代谢靶点及其抑制剂。许多临床批准的抗菌药物和抗癌药物靶向DNA拓扑异构酶。虽然社区缺乏纯的和稳定的疟疾拓扑异构酶的工作，有有趣的提示，从初步数据，临床批准的抗疟药，如咯萘啶，可能会抑制疟疾拓扑异构酶。一项为期三年的NIH资助的研究计划使我们的团队能够表达大量稳定的疟疾拓扑异构酶，为恶性疟原虫拓扑异构酶II和相关酶建立强大的测定方法，并获得疟疾拓扑异构酶II的第一个X射线晶体结构。有了这些资源，在目标1中，我们将开始彻底探索细胞活性抗疟药，以确定领先的PfTopoII抑制剂进行优化。在目标2和3中，迭代药物化学将通过抑制酶和细胞增殖、靶点验证、PK-PD研究、安全性评价和对不同药物的活性来指导。 寄生虫生命周期的各个阶段，所有这些都有助于提供抗疟疾的临床前候选药物。基于 根据我们以前的经验、知识和疟疾二氢乳清酸脱氢酶（DHODH）抑制剂的成功，我们对开发针对恶性疟原虫和间日疟原虫拓扑异构酶的具有临床潜力的抗疟药的能力充满信心。